Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
These results support further development of volrustomig as monotherapy and in combination regimens, with phase 3 trials ongoing.
Authors
- Shelby D. Gainer
- Mark Voskoboynik (ORCID: https://orcid.org/0000-0002-4242-1300)
- E. Carcereny
- Charlotte Lemech (ORCID: https://orcid.org/0000-0002-5399-9431)
- Xuyang Song (ORCID: https://orcid.org/0000-0003-1610-3373)
- Jorge Blando (ORCID: https://orcid.org/0000-0003-3628-6656)
- Pat Mitchell (ORCID: https://orcid.org/0000-0002-3448-4512)
- Ikbel Achour (ORCID: https://orcid.org/0000-0001-6103-4069)
- Florian Song (ORCID: https://orcid.org/0000-0003-4409-438X)
- Julie M. Asare (ORCID: https://orcid.org/0000-0002-3966-4870)
- Shunsuke Kondo (ORCID: https://orcid.org/0000-0001-9565-117X)
- Zoey Tang
- Eduardo Castañón Álvarez (ORCID: https://orcid.org/0000-0003-2957-4414)
- Ben Tran
- Steven Eck
- Sang-We Kim
- Enriqueta Felip
- Myung-Ju Ahn
- James Chih-Hsin. Yang
- Yasutoshi Kuboki
- Ki Hyeong Lee
- Deepa S. Subramaniam
- Daniel Freeman
- Amal Ayyoub
- Paolo Antonio. Ascierto
- Seock-Ah Im
Institutions
- Hebron University (PS)
- Yonsei University (KR)
- Peter MacCallum Cancer Centre (AU)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- University of Ulsan (KR)
- AstraZeneca (South Korea) (KR)
- BioScientia (Poland) (PL)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Brazil) (BR)
- AstraZeneca (Japan) (JP)
- National Taiwan University Hospital (TW)
- Tokyo Women's Medical University Adachi Medical Center (JP)
- Clinica Universidad de Navarra (ES)
- Badalona Serveis Assistencials (ES)
- Tokyo Women's Medical University (JP)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- National Cancer Center Hospital East (JP)
- Hospital Municipal de Badalona (ES)
- Chungbuk National University Hospital (KR)
- Alfred Health (AU)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3447
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Incyte
- Astellas Pharma
- Ipsen
- Genentech
- Daiichi Sankyo Europe